Private Investor, Former Co-CEO McKesson
San Francisco, CA
David Mahoney is a private investor, active board member and recovering consultant. He has been involved in early stage through IPO investments in a variety of companies including FreshPet (FRPT), Foundation Source, Covetrus (CVET), Castle Biosciences (CSTL), Avidity Biosciences (RNA), Stratifi LLC, ID Biologics and Cvictus. In addition, he has served on the boards of public companies (Symantec, Adamas Pharmaceuticals, Tercica) and numerous non-profits (Live Oak School, KQED, Mercy Corps, Mount Holyoke College), generally as chair of key committees. The companies he has been associated with have had five successful FDA approvals, most for first-in-class treatments for serious conditions with poor prognoses. He is currently a director at Corcept Therapeutics (CORT), and a trustee of the Schwab Mutual Funds/ETFs and SFMOMA.
David is the former Co-CEO of McKesson Corporation where he led the strategic re-positioning and subsequent sale of PCS, managed all of the relationships with the pharmaceutical industry including reinventing the way distributors handled generic drugs and helped stabilize the company after the HBOC merger. Prior to that he was a partner at McKinsey and Co. as one of the last generation of generalists, working on industries from sucker rods to satellites.
David has an AB in English from Princeton and an MBA from Harvard Business School. Over the last 40 years, he has built up one of the broadest collections of American photography. He lives in San Francisco with his wife Winn Ellis and two rambunctious dogs, with their two daughters nearby.
DCI Partner: Winn Ellis
